Search

everythinglearnresearchcommunity

for

Search:↓

Dr. Reddy's Mintop Yuva 5 Minoxidil uses benzyl alcohol instead of ethyl alcohol or propylene glycol. The user is inquiring if this formulation causes dandruff or skin peeling and if its efficacy is affected.

Exosome hair therapy involves injecting stem cell-derived exosomes into the scalp to boost hair follicle regeneration and repair. Exosomes, which are not stem cells but products of them, contain bioactive chemicals and specific growth factors that promote new blood vessel formation, increase cell proliferation, reduce inflammation, and improve tissue repair, all crucial for hair health.

Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.

The user experienced hairline recession despite using topical finasteride/minoxidil and is considering whether misapplication was the cause. They are exploring options after experiencing side effects from oral finasteride, including possibly returning to the topical formulation with adjusted application methods.

The conversation discusses creating a 0.01% topical dutasteride solution mixed with minoxidil for hair loss treatment, with concerns about absorption and effectiveness. Some users suggest that dutasteride needs specific formulation for better absorption, while others recommend oral use for practicality.

The post discusses whether a topical serum with 0.3% finasteride, 6% minoxidil, and essential oils is as effective as a spray with the same concentrations but different ingredients for scalp absorption. The user is seeking advice on which formulation absorbs better into the scalp.

The user experienced heart palpitations after increasing their oral minoxidil dosage and starting a new topical minoxidil formulation. They wish to stop oral minoxidil for heart health and continue with topical minoxidil.

The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.

The conversation discusses using Rogaine (Minoxidil) and ketoconazole for hair regrowth, with interest in trying a formulation with Azelaic Acid for potentially better results. Concerns about Azelaic Acid's effectiveness and safety, including skin sensitivity to sunburn, are mentioned.

The user initially started finasteride at 5mg unknowingly, then experimented with various minoxidil formulations, leading to inconsistent results and hair loss. They resumed treatment with topical finasteride and minoxidil, seeing some regrowth, and are now using a more structured regimen while considering a hair transplant.

The conversation is about finding a source for a topical solution combining minoxidil with other ingredients like finasteride, dutasteride, or retinol. The user seeks recommendations for purchasing these enhanced formulations.

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

Minoxidil can cause scalp itchiness, often due to propylene glycol, and users suggest alternatives like foam formulations without PG, using moisturizing oils, or reducing application frequency. Some recommend ketoconazole or zinc pyrithione shampoos to help with inflammation and itchiness.

The user has been using topical finasteride and minoxidil for 5 years, with recent use of a liposomal formulation, but sees no significant improvement. They are considering switching to oral treatments due to continued hair loss and thinning.

The conversation discusses making homemade topical solutions of dutasteride or finasteride using tablets, with suggestions to use alternatives like MinoxidilMax or stemoxydine due to difficulties in formulation. Some users recommend sticking to oral pills for effectiveness and ease.

Minoxidil is causing severe scalp irritation, including itchiness and dryness, for the user. Alternatives suggested include anti-fungal treatments, propylene-glycol-free formulations, and possibly oral minoxidil.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

A user found a solution for Minoxidil-induced dandruff by using a custom NRF 11.121 mixture from a local pharmacy, which includes ingredients like Isopropyl palmitate and Cremophor RH 40. This formulation prevents dryness and allows better penetration when using hair shaders.

The conversation discusses finding a finasteride dosage that reduces DHT by about 25% to minimize side effects, with considerations for topical versus oral formulations. Alternatives like dutasteride mesotherapy and topical treatments are explored, with concerns about systemic absorption and potential impacts on athletic performance and hormone levels.

PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

Topical finasteride with hydroxypropyl chitosan shows significantly less serum absorption and minimal DHT reduction compared to oral finasteride. Users need the specific chitosan formulation to avoid side effects seen with regular ethanol+PG solutions.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

The conversation discusses using a 5% Topical Minoxidil with 0.01% Tretinoin serum for hair loss, noting its lack of propylene glycol to avoid itchiness and greasiness. Users share experiences with different Minoxidil formulations and discuss the effectiveness and stability of Tretinoin in various forms.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.